JP2025510414A - ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体 - Google Patents

ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体 Download PDF

Info

Publication number
JP2025510414A
JP2025510414A JP2025502799A JP2025502799A JP2025510414A JP 2025510414 A JP2025510414 A JP 2025510414A JP 2025502799 A JP2025502799 A JP 2025502799A JP 2025502799 A JP2025502799 A JP 2025502799A JP 2025510414 A JP2025510414 A JP 2025510414A
Authority
JP
Japan
Prior art keywords
compound
disease
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025502799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510414A5 (https=
Inventor
ステファン・ドリチ
アマンディーヌ・シェフソン
ステファン・シブラ
Original Assignee
ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド filed Critical ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド
Publication of JP2025510414A publication Critical patent/JP2025510414A/ja
Publication of JP2025510414A5 publication Critical patent/JP2025510414A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2025502799A 2022-03-25 2023-03-24 ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体 Pending JP2025510414A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US17/704,983 2022-03-25
US202263420930P 2022-10-31 2022-10-31
US63/420,930 2022-10-31
US202363443874P 2023-02-07 2023-02-07
US63/443,874 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (2)

Publication Number Publication Date
JP2025510414A true JP2025510414A (ja) 2025-04-14
JP2025510414A5 JP2025510414A5 (https=) 2026-04-02

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025502799A Pending JP2025510414A (ja) 2022-03-25 2023-03-24 ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体

Country Status (13)

Country Link
EP (1) EP4499638A1 (https=)
JP (1) JP2025510414A (https=)
KR (1) KR20250005125A (https=)
CN (1) CN119137121A (https=)
AU (1) AU2023238121A1 (https=)
CA (1) CA3246681A1 (https=)
CL (1) CL2024002855A1 (https=)
CO (1) CO2024013702A2 (https=)
IL (1) IL315842A (https=)
MX (1) MX2024011697A (https=)
PE (1) PE20250605A1 (https=)
TW (1) TW202345836A (https=)
WO (1) WO2023183943A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
US12331048B2 (en) * 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250106322A (ko) * 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3

Also Published As

Publication number Publication date
MX2024011697A (es) 2024-11-08
IL315842A (en) 2024-11-01
PE20250605A1 (es) 2025-02-26
CA3246681A1 (en) 2023-09-28
CN119137121A (zh) 2024-12-13
WO2023183943A1 (en) 2023-09-28
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CO2024013702A2 (es) 2024-11-08
CL2024002855A1 (es) 2025-02-14
AU2023238121A1 (en) 2024-10-10
EP4499638A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
JP7620120B2 (ja) Ｎｌｒｐ３を阻害するためのピリダジン化合物
JP2025510414A (ja) ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体
US12312351B2 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
HK40100030A (en) Compounds for inhibiting nlrp3 and uses thereof
KR20230157535A (ko) Nlrp3을 저해하기 위한 피리다진 화합물
EA051595B1 (ru) Соединения пиридазина для ингибирования nlrp3
BR122024000756A2 (pt) Compostos inibidores de nlrp3, derivado isotópico dos mesmos, composição farmacêutica que compreende os mesmos, bem como uso dos ditos compostos para tratar ou prevenir uma doença ou distúrbio relacionado a nlrp3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260324

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428